Literature DB >> 7692609

[Alternative therapy of benign prostatic hypertrophy--Permixon (Capistan)].

M Hanus1, M Matousková.   

Abstract

In a multicentre study in four urological departments in the Czech Republic the authors evaluated, based on an elaborated protocol, the effect of the preparation Permixon in patients with complaints associated with benign hyperplasia of the prostate (BPH). They followed-up changes of Goldenberg's symptom score and quantitative indicators of urinary flow, postmicturition residues, the prostate volume and other parameters of the urodynamic examination. Statistical evaluation of the results provided evidence of the effectiveness of the preparation which is considered suitable by the authors, in particular in incipient complaints when the patient complains of discomfort during miction and thus of an altered quality of life.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692609

Source DB:  PubMed          Journal:  Rozhl Chir        ISSN: 0035-9351


  1 in total

Review 1.  Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.